Collegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Sells $313,454.45 in Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Colleen Tupper sold 10,445 shares of the company’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $30.01, for a total value of $313,454.45. Following the completion of the transaction, the chief financial officer now directly owns 165,246 shares in the company, valued at $4,959,032.46. This represents a 5.95 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Colleen Tupper also recently made the following trade(s):

• On Thursday, March 6th, Colleen Tupper sold 1,949 shares of Collegium Pharmaceutical stock. The stock was sold at an average price of $30.00, for a total value of $58,470.00.

Collegium Pharmaceutical Trading Up 1.2 %

Shares of NASDAQ COLL opened at $29.46 on Friday. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a one year low of $27.28 and a one year high of $42.29. The business has a 50-day moving average price of $30.85 and a two-hundred day moving average price of $32.99. The firm has a market capitalization of $927.58 million, a PE ratio of 12.70 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.54 by $0.09. The business had revenue of $181.95 million during the quarter, compared to analysts’ expectations of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. As a group, analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

COLL has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research note on Friday, January 10th. Finally, Piper Sandler dropped their target price on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 4th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and an average target price of $43.60.

Hedge Funds Weigh In On Collegium Pharmaceutical

Hedge funds have recently modified their holdings of the stock. New Age Alpha Advisors LLC acquired a new stake in Collegium Pharmaceutical during the fourth quarter valued at $40,000. TD Private Client Wealth LLC raised its stake in shares of Collegium Pharmaceutical by 39.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after purchasing an additional 483 shares in the last quarter. Virtus Fund Advisers LLC acquired a new stake in shares of Collegium Pharmaceutical during the 3rd quarter valued at about $72,000. KBC Group NV grew its stake in shares of Collegium Pharmaceutical by 72.5% in the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock valued at $67,000 after buying an additional 982 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after buying an additional 316 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.